Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy.

Cancer·2026

Same author

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.

PharmacoEconomics - open·2026

Same author

Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events.

Journal of the National Cancer Institute·2026

Same author

A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population.

Journal of medical economics·2025

Same author

Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer.

Cancer medicine·2025

Same author

Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Published on: December 18, 2010

Granulocyte colony-stimulating factors: finding the right indication.

Gary H Lyman¹, Michelle Shayne

¹University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. Gary_Lyman@urmc.rochester.edu

Current Opinion in Oncology

|June 5, 2007

Summary

Recombinant myeloid growth factors effectively reduce neutropenic complications in cancer patients undergoing chemotherapy. Updated guidelines recommend their prophylactic use for patients at high risk of febrile neutropenia.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Published on: December 18, 2010

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Neutropenic complications, such as febrile neutropenia, are significant dose-limiting toxicities in cancer chemotherapy.
Recombinant myeloid growth factors are used to mitigate these risks and maintain chemotherapy dose intensity.

Purpose of the Study:

To review current recommendations for the use of recombinant myeloid growth factors in cancer chemotherapy.
To present the evidence base and recommendations from three major oncology organizations' guidelines.

Main Methods:

Review of randomized controlled trials and meta-analyses on myeloid growth factor efficacy.
Analysis of recent clinical practice guidelines from the American Society of Clinical Oncology, European Organization for Research and Treatment of Cancer, and National Comprehensive Cancer Network.

Main Results:

Myeloid growth factors reduce the risk of neutropenic complications and can facilitate chemotherapy dose intensity.
Older age and comorbidities increase the risk of febrile neutropenia.
New guidelines recommend prophylactic myeloid growth factor use for patients with a ≥20% risk of febrile neutropenia or other high-risk factors.

Conclusions:

Consistent clinical practice guidelines support the appropriate and cost-effective use of myeloid growth factors.
Evidence from multiple trials and meta-analyses underpins these recommendations.